- Home
- EDIT vs PHD Comparison
EDIT vs PHD Comparison
Compare EDIT & PHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- PHD
- Stock Information
- Founded
- EDIT 2013
- PHD 2004
- Country
- EDIT United States
- PHD United States
- Employees
- EDIT N/A
- PHD N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- PHD Investment Managers
- Sector
- EDIT Health Care
- PHD Finance
- Exchange
- EDIT Nasdaq
- PHD Nasdaq
- Market Cap
- EDIT 115.5M
- PHD 120.3M
- IPO Year
- EDIT 2016
- PHD N/A
- Fundamental
- Price
- EDIT $1.79
- PHD $9.77
- Analyst Decision
- EDIT Buy
- PHD
- Analyst Count
- EDIT 13
- PHD 0
- Target Price
- EDIT $6.73
- PHD N/A
- AVG Volume (30 Days)
- EDIT 1.9M
- PHD 67.7K
- Earning Date
- EDIT 05-12-2025
- PHD 01-01-0001
- Dividend Yield
- EDIT N/A
- PHD 11.43%
- EPS Growth
- EDIT N/A
- PHD N/A
- EPS
- EDIT N/A
- PHD 1.27
- Revenue
- EDIT $35,837,000.00
- PHD N/A
- Revenue This Year
- EDIT N/A
- PHD N/A
- Revenue Next Year
- EDIT N/A
- PHD N/A
- P/E Ratio
- EDIT N/A
- PHD $7.60
- Revenue Growth
- EDIT N/A
- PHD N/A
- 52 Week Low
- EDIT $0.91
- PHD $8.30
- 52 Week High
- EDIT $6.22
- PHD $9.81
- Technical
- Relative Strength Index (RSI)
- EDIT 60.00
- PHD 64.62
- Support Level
- EDIT $1.70
- PHD $9.70
- Resistance Level
- EDIT $1.95
- PHD $9.78
- Average True Range (ATR)
- EDIT 0.15
- PHD 0.06
- MACD
- EDIT 0.03
- PHD -0.01
- Stochastic Oscillator
- EDIT 76.03
- PHD 70.00
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About PHD Pioneer Floating Rate Fund Inc.
Pioneer Floating Rate Trust is a diversified, closed-end fund. It invests in the fixed income markets of the United States. The fund basically invests in senior secured floating-rate loans. It benchmarks the performance of its portfolio against the other High Yield Loans Index banks.